A self-regulated anti-diabetic drug release device mimicking pancreatic cells is highly desirable for the therapy of diabetes. Herein, a glucose-mediated dual-responsive drug delivery system, which combines pH-and H_(...A self-regulated anti-diabetic drug release device mimicking pancreatic cells is highly desirable for the therapy of diabetes. Herein, a glucose-mediated dual-responsive drug delivery system, which combines pH-and H_(2)O_(2)-responsive block copolymer grafted hollow mesoporous silica nanoparticles(HMSNs)with microneedle(MN) array patch, has been developed to achieve self-regulated administration.The poly[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acrylate]-b-poly[2-(dimethylamino)ethyl methacrylate](PPBEM-b-PDM) polymer serves as gate keeper to prevent drug release from the cavity of HMSNs at normoglycemic level. In contrast, the drug release rate is significantly enhanced upon H_(2)O_(2)and pH stimuli due to the chemical change of H_(2)O_(2)sensitive PPBEM block and acid responsive PDM block. Therefore, incorporation of anti-diabetic drug and glucose oxidase(GOx, which can oxidize glucose to gluconic acid and in-situ produce H_(2)O_(2)) into stimulus polymer coated HMSNs results in a glucose-mediated MN device after depositing the drug-loaded nanoparticles into MN array patch. Both in vitro and in vivo results show this MN device presents a glucose mediated self-regulated drug release characteristic, which possesses a rapid drug release at hyperglycemic level but retarded drug release at normoglycemic level. The result indicates that the fabricated smart drug delivery system is a good candidate for the therapy of diabetes.展开更多
A glucose-mediated drug delivery system would be highly satisfactory fordiabetes diagnosis since it can intelligently release drug based on blood glucose levels.Herein,a glucose-responsive drug delivery system by inte...A glucose-mediated drug delivery system would be highly satisfactory fordiabetes diagnosis since it can intelligently release drug based on blood glucose levels.Herein,a glucose-responsive drug delivery system by integrating glucose-responsivepoly(3-acrylamidophenylboronic acid)(PAPBA)functionalized hollow mesoporous silicananoparticles(HMSNs)with transcutaneous microneedles(MNs)has been designed.Thegrafted PAPBA serves as gatekeeper to prevent drug release from HMSNs atnormoglycemic levels.In contrast,faster drug release is detected at a typicalhyperglycemic level,which is due to the change of hydrophilicity of PAPBA at highglucose concentration.After transdermal administration to diabetic rats,an effectivehypoglycemic effect is achieved compared with that of subcutaneous injection.Theseobservations indicate that the designed glucose-responsive drug delivery system has apotential application in diabetes treatment.展开更多
Smart drug delivery nanocarriers with high drug loading capacity are of great importance in the treatment of diseases,and can improve therapeutic effectiveness as well as alleviate side effects in patients.In this wor...Smart drug delivery nanocarriers with high drug loading capacity are of great importance in the treatment of diseases,and can improve therapeutic effectiveness as well as alleviate side effects in patients.In this work,a pH and H_(2)O_(2)-responsive drug delivery platform with high doxorubicin(DOX)loading capacity has been established through coordination interaction between DOX and phenylboronic acid containing block polymer.A composited drug nanocarrier is further fabricated by growing a zeolitic imidazolate framework 8(ZIF-8)on the surface of drug-loaded polymer micelles.The study verifies that ZIF-8 shell can act as intelligent“switch”to prevent DOX leaking from core–shell nanoparticles upon H_(2)O_(2) stimulus.However,a burst drug release is detected upon pH and H_(2)O_(2) stimuli due to the further disassociation of ZIF-8 in acid solution.Moreover,the in vitro anti-cancer experiments demonstrate that the DOX-loaded core–shell nanoparticles provide effective treatment towards cancer cells but have negligible effect on normal cells,which results from the high concentration of H_(2)O_(2) and low pH in the microenvironment of tumor cells.展开更多
基金financially supported by the Zhejiang Provincial Natural Science Foundation of China (LY20E030005)Natural Science Foundation of Zhejiang Education Department (Y201942793)the Opening Project of Jiangxi Province Key Laboratory of Polymer Micro/Nano Manufacturing and Devices (PMND201905)。
文摘A self-regulated anti-diabetic drug release device mimicking pancreatic cells is highly desirable for the therapy of diabetes. Herein, a glucose-mediated dual-responsive drug delivery system, which combines pH-and H_(2)O_(2)-responsive block copolymer grafted hollow mesoporous silica nanoparticles(HMSNs)with microneedle(MN) array patch, has been developed to achieve self-regulated administration.The poly[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acrylate]-b-poly[2-(dimethylamino)ethyl methacrylate](PPBEM-b-PDM) polymer serves as gate keeper to prevent drug release from the cavity of HMSNs at normoglycemic level. In contrast, the drug release rate is significantly enhanced upon H_(2)O_(2)and pH stimuli due to the chemical change of H_(2)O_(2)sensitive PPBEM block and acid responsive PDM block. Therefore, incorporation of anti-diabetic drug and glucose oxidase(GOx, which can oxidize glucose to gluconic acid and in-situ produce H_(2)O_(2)) into stimulus polymer coated HMSNs results in a glucose-mediated MN device after depositing the drug-loaded nanoparticles into MN array patch. Both in vitro and in vivo results show this MN device presents a glucose mediated self-regulated drug release characteristic, which possesses a rapid drug release at hyperglycemic level but retarded drug release at normoglycemic level. The result indicates that the fabricated smart drug delivery system is a good candidate for the therapy of diabetes.
文摘A glucose-mediated drug delivery system would be highly satisfactory fordiabetes diagnosis since it can intelligently release drug based on blood glucose levels.Herein,a glucose-responsive drug delivery system by integrating glucose-responsivepoly(3-acrylamidophenylboronic acid)(PAPBA)functionalized hollow mesoporous silicananoparticles(HMSNs)with transcutaneous microneedles(MNs)has been designed.Thegrafted PAPBA serves as gatekeeper to prevent drug release from HMSNs atnormoglycemic levels.In contrast,faster drug release is detected at a typicalhyperglycemic level,which is due to the change of hydrophilicity of PAPBA at highglucose concentration.After transdermal administration to diabetic rats,an effectivehypoglycemic effect is achieved compared with that of subcutaneous injection.Theseobservations indicate that the designed glucose-responsive drug delivery system has apotential application in diabetes treatment.
基金financially supported by the Natural Science Foundation of Zhejiang Province(No.LY20E030005)。
文摘Smart drug delivery nanocarriers with high drug loading capacity are of great importance in the treatment of diseases,and can improve therapeutic effectiveness as well as alleviate side effects in patients.In this work,a pH and H_(2)O_(2)-responsive drug delivery platform with high doxorubicin(DOX)loading capacity has been established through coordination interaction between DOX and phenylboronic acid containing block polymer.A composited drug nanocarrier is further fabricated by growing a zeolitic imidazolate framework 8(ZIF-8)on the surface of drug-loaded polymer micelles.The study verifies that ZIF-8 shell can act as intelligent“switch”to prevent DOX leaking from core–shell nanoparticles upon H_(2)O_(2) stimulus.However,a burst drug release is detected upon pH and H_(2)O_(2) stimuli due to the further disassociation of ZIF-8 in acid solution.Moreover,the in vitro anti-cancer experiments demonstrate that the DOX-loaded core–shell nanoparticles provide effective treatment towards cancer cells but have negligible effect on normal cells,which results from the high concentration of H_(2)O_(2) and low pH in the microenvironment of tumor cells.
